Generic drug maker Actavis Inc (NYSE:ACT) is reported to have spurned a $15 billion cash and stock acquisition offer from Mylan Inc. (NASDAQ:MYL). According to Bloomberg, Actavis Inc (NYSE:ACT) would decide instead to pursue talks to take over the Irish drug maker Warner Chilcott Plc (NASDAQ:WCRX). Earlier, Watson Pharmaceuticals completed its acquisition of the then Switzerland-based privately-held Actavis Group in a deal valued at about 4.25 billion euros or $5.6 billion in October. It then renamed itself Actavis, Inc. Following the Watson-Actavis deal, Actavis became the second largest global generic drug maker and the largest in the U.S. Prior to the…
Actavis Rejects Mylan Offer [REPORT]
Mani
Mani is a Senior Financial Consultant. He has worked in Senior Management role in large banking, financial and information technology organizations. He has provided solutions for major banking and securities firms across the globe in the area of retail, corporate and investment banking. He holds MBA (Finance) and Professional Management Accounting Qualifications. His hobbies are tracking global financial developments and watching sports